Anti-tumor activity of ESX1 on cancer cells harboring oncogenic K-ras mutation

Area of Science:

• Molecular biology
• Oncology
• Gene regulation

Background:

• Human ESX1 is a homeoprotein processed into N-terminal (N-ESX1) and C-terminal fragments.
• N-ESX1 contains the homeodomain and functions as a transcriptional repressor of the K-ras gene.

Purpose of the Study:

• To investigate the in vivo therapeutic potential of N-ESX1 in human cancers with oncogenic K-ras mutations.
• To evaluate the efficacy of N-ESX1, especially when delivered via protein transduction, in reducing tumor formation.

Main Methods:

• Inoculation of human colorectal carcinoma HCT116 cells expressing N-ESX1 into nude mice.
• Treatment of HCT116 cells with a fusion protein of N-ESX1 and the HIV-1 TAT protein transduction domain.
• Assessment of tumor-forming activity and tumorigenicity in vivo.

Main Results:

• HCT116 cells constitutively expressing N-ESX1 exhibited decreased tumor-forming activity compared to parental cells.
• Pretreatment with the N-ESX1-TAT fusion protein significantly reduced the tumorigenicity of HCT116 cells in nude mice.
• These findings demonstrate the in vivo anti-cancer effects of N-ESX1.

Conclusions:

• ESX1, specifically its N-terminal fragment (N-ESX1), is a potential molecular target for cancer therapy.
• TAT-mediated transduction of N-ESX1 offers a promising strategy for treating human cancers with K-ras mutations.
• This study provides the first in vivo evidence for the therapeutic application of ESX1 in cancer treatment.